Pneumagen Ltd Announces Positive Anti–Viral Activity for Novel Glycan Approach in Preventing COVID–19 Infections
Pneumagen Ltd Leverages its Novel Glycan Approach to Target Coronavirus (COVID-19) Infections
Pneumagen Presents Poster on Multivalent Sialic Acid-binding Proteins as a Novel Preventative and Treatment of RSV at RSVVW 2019
Pneumagen Demonstrates Preclinical Proof-of-Concept in Oncology for Neumonco, a Novel Carbohydrate Binding Module
Pneumagen Demonstrates Preclinical Proof-of-Concept for Neumifil™ in Respiratory Syncytial Virus Infections
Pneumagen Appoints Scientific Advisory Board
Publication – Sialic Acid-Binding Protein Sp2CBMTD Protects Mice against Lethal Challenge with Emerging Influenza A (H7N9) Virus
PUBLICATION – Prevention of influenza by targeting host receptors using engineered proteins
Bio€quity Europe in Dublin | May 14th – 16th 2023
BioTrinity in London | April 25 – 26th 2023
Biotech Showcase / JPM Week | January 9th – 11th 2023
Jefferies London Healthcare Conference | November 15th – 17th 2022
BIO-Europe in Leipzig | October 24th – 26th 2022
BIO International Convention in San Diego | June 13th – 16th 2022
Bio€quity Europe in Milan | May 16th – 18th 2022
BioTrinity 2022 in London | April 26th – 27th 2022
BIO-Europe Spring Digital | March 28th – 30th 2022
